Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

432 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Active Aβ immunotherapy CAD106 in Alzheimer's disease: A phase 2b study.
Vandenberghe R, Riviere ME, Caputo A, Sovago J, Maguire RP, Farlow M, Marotta G, Sanchez-Valle R, Scheltens P, Ryan JM, Graf A. Vandenberghe R, et al. Among authors: ryan jm. Alzheimers Dement (N Y). 2016 Dec 23;3(1):10-22. doi: 10.1016/j.trci.2016.12.003. eCollection 2017 Jan. Alzheimers Dement (N Y). 2016. PMID: 29067316 Free PMC article.
Improving Alzheimer's disease phase II clinical trials.
Greenberg BD, Carrillo MC, Ryan JM, Gold M, Gallagher K, Grundman M, Berman RM, Ashwood T, Siemers ER. Greenberg BD, et al. Among authors: ryan jm. Alzheimers Dement. 2013 Jan;9(1):39-49. doi: 10.1016/j.jalz.2012.02.002. Epub 2012 Nov 16. Alzheimers Dement. 2013. PMID: 23164548
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Salloway S, et al. N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839. N Engl J Med. 2014. PMID: 24450891 Free PMC article. Clinical Trial.
Active immunotherapy options for Alzheimer's disease.
Winblad B, Graf A, Riviere ME, Andreasen N, Ryan JM. Winblad B, et al. Among authors: ryan jm. Alzheimers Res Ther. 2014 Jan 30;6(1):7. doi: 10.1186/alzrt237. eCollection 2014. Alzheimers Res Ther. 2014. PMID: 24476230 Free PMC article. Review.
The Alzheimer's Prevention Initiative Generation Program: Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer's disease.
Lopez Lopez C, Tariot PN, Caputo A, Langbaum JB, Liu F, Riviere ME, Langlois C, Rouzade-Dominguez ML, Zalesak M, Hendrix S, Thomas RG, Viglietta V, Lenz R, Ryan JM, Graf A, Reiman EM. Lopez Lopez C, et al. Among authors: ryan jm. Alzheimers Dement (N Y). 2019 Jun 12;5:216-227. doi: 10.1016/j.trci.2019.02.005. eCollection 2019. Alzheimers Dement (N Y). 2019. PMID: 31211217 Free PMC article. Review.
In vivo tau pathology is associated with synaptic loss and altered synaptic function.
Coomans EM, Schoonhoven DN, Tuncel H, Verfaillie SCJ, Wolters EE, Boellaard R, Ossenkoppele R, den Braber A, Scheper W, Schober P, Sweeney SP, Ryan JM, Schuit RC, Windhorst AD, Barkhof F, Scheltens P, Golla SSV, Hillebrand A, Gouw AA, van Berckel BNM. Coomans EM, et al. Among authors: ryan jm. Alzheimers Res Ther. 2021 Feb 5;13(1):35. doi: 10.1186/s13195-021-00772-0. Alzheimers Res Ther. 2021. PMID: 33546722 Free PMC article.
Kinetics and 28-day test-retest repeatability and reproducibility of [11C]UCB-J PET brain imaging.
Tuncel H, Boellaard R, Coomans EM, de Vries EF, Glaudemans AW, Feltes PK, García DV, Verfaillie SC, Wolters EE, Sweeney SP, Ryan JM, Ivarsson M, Lynch BA, Schober P, Scheltens P, Schuit RC, Windhorst AD, De Deyn PP, van Berckel BN, Golla SS. Tuncel H, et al. Among authors: ryan jm. J Cereb Blood Flow Metab. 2021 Jun;41(6):1338-1350. doi: 10.1177/0271678X20964248. Epub 2020 Oct 8. J Cereb Blood Flow Metab. 2021. PMID: 34013797 Free PMC article.
Rationale for the selection of dual primary endpoints in prevention studies of cognitively unimpaired individuals at genetic risk for developing symptoms of Alzheimer's disease.
Caputo A, Racine A, Paule I, Tariot PN, Langbaum JB, Coello N, Riviere ME, Ryan JM, Lopez CL, Graf A; National Alzheimer’s Coordinating Center; Alzheimer’s Disease Neuroimaging Initiative. Caputo A, et al. Among authors: ryan jm. Alzheimers Res Ther. 2023 Mar 6;15(1):45. doi: 10.1186/s13195-023-01183-z. Alzheimers Res Ther. 2023. PMID: 36879340 Free PMC article.
Dependence as a unifying construct in defining Alzheimer's disease severity.
McLaughlin T, Feldman H, Fillit H, Sano M, Schmitt F, Aisen P, Leibman C, Mucha L, Ryan JM, Sullivan SD, Spackman DE, Neumann PJ, Cohen J, Stern Y. McLaughlin T, et al. Among authors: ryan jm. Alzheimers Dement. 2010 Nov;6(6):482-93. doi: 10.1016/j.jalz.2009.09.004. Alzheimers Dement. 2010. PMID: 21044778 Free PMC article. Review.
432 results